NEW YORK, Jan 12, 2026, 15:29 (EST) — Trading in the regular session.
- Shares of Caris Life Sciences dropped roughly 9% in afternoon trading following the release of preliminary revenue numbers for 2025.
- The company estimated fourth-quarter revenue around $281 million and full-year revenue near $800 million, though it warned of significant prior-period adjustments affecting these figures.
- Caris revealed a new partnership with Everlywell focused on an upcoming early cancer-screening test, with investors awaiting additional details during a JPMorgan conference presentation later Monday.
Caris Life Sciences shares dropped roughly 8.5% to $26.08 in afternoon trading, after fluctuating between $25.35 and $29.77 earlier today.
The update comes amid J.P. Morgan Healthcare Conference week, a time when healthcare firms typically try to recalibrate expectations ahead of earnings season. Investors are focused on whether Caris can maintain its growth pace without relying on one-off factors.
Caris faces a tight deadline to control the story. The company is set to present at the conference later Monday, but the stock’s steep drop signals that traders are looking for more than just a jump in top-line numbers.
Caris reported preliminary fourth-quarter revenue at around $281 million, marking a roughly 116% jump from the previous year. Full-year revenue came in near $800 million, up about 94%. The company said molecular profiling services brought in approximately $270 million in the quarter, which included some $81 million in “prior period true-ups” — accounting adjustments for previous periods. Pharma research and development services added about $11 million. Caris wrapped up 2025 with roughly $802 million in cash, cash equivalents, restricted cash, and marketable securities. It plans to release full results during an earnings call in late February 2026. “2025 was a breakthrough year for Caris as we became a public company,” CEO David D. Halbert said. 1
Caris announced a partnership with Everlywell to develop Caris Detect, a blood-based multi-cancer early detection (MCED) test. The assay will leverage whole genome sequencing, with a planned rollout in the first half of 2026. Everlywell CEO Julia Cheek said the collaboration aims to “enhance access” to the screening. 2
Before the open, the stock was headed in the opposite direction. CAI shares climbed roughly 3.5% in premarket action, hitting $29.50 following the early revenue report, Nasdaq.com said. 3
Evercore ISI analyst Vijay Kumar noted in a recent report that “pharma contracting revenue missed expectations, though diagnostics sales beat,” according to Investors.com. That same story highlighted sharp fluctuations in diagnostics and med-tech stocks during conference-week updates, underscoring how the JPMorgan meeting can swing sentiment on a headline within minutes. 4
That said, there are clear risks. The company flagged these numbers as preliminary and unaudited, leaving room for doubt about how sustainable the quarter’s revenue will be once those big true-ups drop out. Plus, new initiatives like the MCED screening test carry their own execution risks—everything from timing to customer adoption remains uncertain.
The company’s conference presentation is slated for 1:30 p.m. Pacific time on Monday. Investors will be watching closely for clearer insight into revenue streams and demand trends. Following that, the late-February earnings call will serve as the next major event, with Caris set to release audited 2025 results and provide guidance for 2026.
